Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H, Fujimura A, Hayashi K, Kimura T, Ni Y, Otoda T, Miyamoto K, Zen Y, Nakanuma Y, Kaneko S. Kita Y, et al. Among authors: misu h. PLoS One. 2012;7(9):e43056. doi: 10.1371/journal.pone.0043056. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028442 Free PMC article.
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.
Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S. Otoda T, et al. Among authors: misu h. Diabetes. 2013 Mar;62(3):811-24. doi: 10.2337/db11-1652. Epub 2012 Dec 3. Diabetes. 2013. PMID: 23209186 Free PMC article.
LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance.
Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, Takata N, Hayashi H, Matsuzawa-Nagata N, Takeshita Y, Noda H, Matsumoto Y, Ota T, Nagano T, Nakagen M, Miyamoto K, Takatsuki K, Seo T, Iwayama K, Tokuyama K, Matsugo S, Tang H, Saito Y, Yamagoe S, Kaneko S, Takamura T. Lan F, et al. Among authors: misu h. Diabetes. 2014 May;63(5):1649-64. doi: 10.2337/db13-0728. Epub 2014 Jan 29. Diabetes. 2014. PMID: 24478397 Free article.
Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.
Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, Yamada M, Misu H, Matsushima Y, Kaneko S; Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group. Takeshita Y, et al. Among authors: misu h. J Diabetes Investig. 2015 Mar;6(2):192-200. doi: 10.1111/jdi.12269. Epub 2014 Sep 9. J Diabetes Investig. 2015. PMID: 25802727 Free PMC article.
Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study.
Shima KR, Ota T, Kato KI, Takeshita Y, Misu H, Kaneko S, Takamura T. Shima KR, et al. Among authors: misu h. BMJ Open Diabetes Res Care. 2018 Mar 17;6(1):e000469. doi: 10.1136/bmjdrc-2017-000469. eCollection 2018. BMJ Open Diabetes Res Care. 2018. PMID: 29607050 Free PMC article.
87 results